The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
The placebo response is a major issue in clinical trials for psychiatric disorders. Possible contributing factors to this problem include diagnostic misclassification, issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to change, measurement errors, poor quality of data entry and verification, waxing and waning of the natural course of illness, regression toward the mean phenomenon, patient and clinician expectations about the trial, study design issues, non-specific therapeutic effects, and high attrition. Over the past few decades, researchers have attempted to reduce the placebo effect in a variety of ways. Unfortunately, approaches with very little or no benefit have included restricting enrollment to selected populations, rater training, requirement of same rater, and placebo lead-in phases. Some benefits, although often marginal, have been derived from standardizing diagnostic procedures, managing clinicians’ overestimation of change, simplification of study visits and assessments, minimizing non-specific, therapeutic effects, extending trial duration, reducing number of sites, increasing the sensitivity of outcome measures, and reducing the number of treatment arms. Thus far, there has been no attempt to develop new study designs aimed at reducing the placebo effect. We are proposing a novel study design, called ‘Sequential Parallel Comparison Design’, suitable for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for such trials. Its usefulness in clinical research needs to be tested empirically. If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [162]
Citations
Cites
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“These numbers are even more impressive as most negative trials are typically unpublished, suggesting that the average placebo response rate in MDD trials is probably closer to the 35–45p range.Similarly, in smoking cessation trials, the placebo response rate has progressively increased. For example, in a recent study…”
ResultIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
A Primer on Regression Artifacts
Campbell, D. T., & Kenny, D. A. (1999) · Medical Entomology and Zoology · Cited by 482
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Linear Statistical Inference and its Applications.
Moore, P. G., & Rao, C. R. (1967) · The Statistician · doi:10.2307/2987205 · Cited by 439
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427 · cited 1×
“Another useful approach is to use outcome measures that can be administered in both clinician- and patient-rated forms, as in the case of the Inventory of Depressive Symptomatology (IDS) [”
MethodThe Hamilton Depression Scale: EVALUATION OF OBJECTIVITY USING LOGISTIC MODELS
Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00676.x · Cited by 425
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
Research works printed but not linked: 2
- 10.1001/jama.271.24.1940 · doi:10.1001/jama.271.24.1940 · Paper page
- 10.1037//0022-006x.70.4.887 · doi:10.1037//0022-006x.70.4.887
Cited by
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
“Regression to the mean may further foster the invalid impression of symptomatic improvement (Fava et al, 2003a).”
Background(2020) · doi:10.1056/nejmra1907805 · Cited by 634
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
“Of note, when using symptom severity as a clinical trial inclusion criterion, if the same scale is used to measure symptoms at baseline and to determine entry into the study (above a certain threshold on a symptom rating scale), regression to the mean will further contribute to the invalid impression of symptomatic im…”
MethodPrognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
“[117] Fava M, Evins AE, Dorer DJ, Schoenfeld DA.”
BackgroundMethodNeacsiu, A. D., Eberle, J. W., Kramer, R., Wiesmann, T., & Linehan, M. M. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.05.005 · Cited by 394
Papakostas, G. I., & Fava, M. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.009 · Cited by 382
“This would support the use of the sequential parallel comparison design, which does capitalize on the use of shorter treatment durations (Fava et al., 2003).”
BackgroundMethodIntranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705521114 · Cited by 349
“Placebo responses are frequently reported in psychiatric clinical trials (30), including trials in ASD (19, 22, 31).”
BackgroundEfficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347
“argues that this progressively increasing response to both compromises the ability to differentiate truly efficacious antidepressants from placebos, particularly among less severe patients.Fava et al. [”
BackgroundMeta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346
“Following the view of Fava and others (Fava et al., 2003), this effect might indicate increasing overestimation of positive effects by clinicians.”
BackgroundBlinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Placebo Effects: From the Neurobiological Paradigm to Translational Implications
Benedetti, F. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.023 · Cited by 317
“Many new designs have been devised in different medical conditions, such as depression (Fava et al., 2003), and different placebo components have been described within the setting of a clinical trial (Kaptchuk et al.”
Fried, E. I., van Borkulo, C. D., Epskamp, S., Schoevers, R. A., Tuerlinckx, F., & Borsboom, D. (2016) · Psychological Assessment · doi:10.1037/pas0000275 · Cited by 314
“RTTM is known to influence the results of antidepressants trials, and, as expected, especially severe in studies with very high severity thresholds (Fava, Evins, Dorer, & Schoenfeld, 2003).”
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Burke, L. B., Farrar, J. T., Gilron, I., Jensen, M. P., Katz, N. P., Raja, S. N., Rappaport, B. A., et al. (2012) · Pain · doi:10.1016/j.pain.2012.03.003 · Cited by 285
“The use of single-blind placebo run-ins has not appeared to increase assay sensitivity in psychiatry RCTs [25] or in a recent trial in patients with posttraumatic peripheral neuropathic pain [98].”
BackgroundPapakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Bupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071114 · Cited by 275
Self-citationThe Placebo Effect in Pain Therapies
Colloca, L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021542 · Cited by 270
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232
Green, J. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2005.01516.x · Cited by 193
Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects
Benedetti, F., Carlino, E., & Piedimonte, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00066-1 · Cited by 183
Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations
Smith, S. M., Dworkin, R. H., Turk, D. C., McDermott, M. P., Eccleston, C., Farrar, J. T., Rowbotham, M. C., Bhagwagar, Z., Burke, L. B., Cowan, P., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001952 · Cited by 194
Self-citationReproducibility of placebo analgesia: Effect of dispositional optimism
Morton, D. L., Watson, A., El-Deredy, W., & Jones, A. K. P. (2009) · Pain · doi:10.1016/j.pain.2009.07.026 · Cited by 190
“Placebo effects have been held responsible for the failure of many clinical trials at a high cost to the pharmaceutical industry [10,22,31].”
BackgroundClinimetric Criteria for Patient-Reported Outcome Measures
Carrozzino, D., Patierno, C., Guidi, J., Berrocal Montiel, C., Cao, J., Charlson, M. E., Christensen, K. S., Concato, J., De las Cuevas, C., de Leon, J., et al. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000516599 · Cited by 177
Assessing general side effects in clinical trials: reference data from the general population
Rief, W., Barsky, A. J., Glombiewski, J. A., Nestoriuc, Y., Glaesmer, H., & Braehler, E. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2067 · Cited by 165
“Moreover, it has been shown that some physicians tend to disregard patient reports on adverse drug events.(19,28) If investigator’s expectation determines partially the rate of reported side effects in clinical trials, alternative methodological approaches are necessary to decide whether symptoms are drug induced.”
BackgroundClinical trial outcome in neuropathic pain: Relationship to study characteristics
Katz, J., Finnerup, N. B., & Dworkin, R. H. (2008) · Neurology · doi:10.1212/01.wnl.0000275528.01263.6c · Cited by 169
Peciña, M., Bohnert, A. M., Sikora, M., Avery, E. T., Langenecker, S. A., Mickey, B. J., & Zubieta, J. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1335 · Cited by 159
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“The rate was low and difficult to attribute to specific effects of citalopram, since a variety of non-specific therapeutic ingredients, as in the other major trials were used (Fava et al., 2003).”
Do “placebo responders” exist?
Kaptchuk, T. J., Kelley, J. M., Deykin, A., Wayne, P. M., Lasagna, L. C., Epstein, I. O., Kirsch, I., & Wechsler, M. E. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.02.002 · Cited by 151
“Then, as now, high placebo response rates in RCTs threatened the detection of an active pharmacological effect [15–18].”
BackgroundPsychometric Theory Is an Obstacle to the Progress of Clinical Research
Fava, G. A., Ruini, C., & Rafanelli, C. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000076451 · Cited by 143
“In the past decade, there has been an increasing number of trials which have failed to display significant differences between psychotropic drugs and placebo [”
BackgroundEfficacy of Cognitive Behaviour Therapy in Generalized Anxiety Disorders
Linden, M., Zubraegel, D., Baer, T., Franke, U., & Schlattmann, P. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082025 · Cited by 142
“The statistical analyses of treatment outcome were conservative in two ways. The pre-treatment assessment took place after two intake sessions with the therapist, and thus initial spontaneous changes in the psychopathological status are not counted as treatment effects. This is one way of reducing placebo effects [”
BackgroundFava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Papakostas, G. I., Shelton, R. C., Zajecka, J., Bottiglieri, T., Roffman, J. L., Cassiello-Robbins, C. F., Stahl, S. M., & D, M. F. M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08947 · Cited by 143
“001 2 BMI ≥ 30 kg/m2 + DRD2 TC/TT 10 (17) −9.”
Depressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136
Drug-Induced Depression: A Systematic Review to Inform Clinical Practice
Patten, S. B., & Barbui, C. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000077739 · Cited by 144
Seasonal Affective Disorder and Its Prevention by Anticipatory Treatment with Bupropion XL
Modell, J. G., Rosenthal, N. E., Harriett, A. E., Krishen, A., Asgharian, A., Foster, V. J., Metz, A. L., Rockett, C. B., & Wightman, D. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.021 · Cited by 139
Placebo response to manual therapy: something out of nothing?
Bialosky, J. E., Bishop, M. D., George, S. Z., & Robinson, M. E. (2011) · Journal of Manual & Manipulative Therapy · doi:10.1179/2042618610y.0000000001 · Cited by 145
Stein, D. J., Baldwin, D. S., Dolberg, O. T., Despiégel, N., & Bandelow, B. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1111 · Cited by 122
Correll, C. U., Solmi, M., Cortese, S., D, M. F. M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 120
Dworkin, R. H., Katz, J., & Gitlin, M. J. (2005) · Neurology · doi:10.1212/wnl.65.12_suppl_4.s7 · Cited by 116
Mitigating the Effects of Nonadherence in Clinical Trials
Shiovitz, T. M., Bain, E. E., McCann, D. J., Skolnick, P., Laughren, T., Hanina, A., & Burch, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.689 · Cited by 114
Subtyping Major Depressive Disorder
Lichtenberg, P., & Belmaker, R. H. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000286957 · Cited by 117
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations
Gewandter, J. S., Dworkin, R. H., Turk, D. C., McDermott, M. P., Baron, R., Gastonguay, M. R., Gilron, I., Katz, N. P., Mehta, C. R., Raja, S. N., et al. (2014) · Pain · doi:10.1016/j.pain.2014.05.025 · Cited by 117
“Sequential parallel comparison designs (SPCD) incorporate stage 1 data and stage 2 data from stage 1 placebo non-responders only, potentially decreasing the impact of the placebo response [32].”
BackgroundMethodThe Road to Recovery from Depression – Don’t Drive Today with Yesterday’s Map
Fava, G. A., Tomba, E., & Grandi, S. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104701 · Cited by 113
Abdallah, C. G., Roache, J. D., Gueorguieva, R., Averill, L. A., Young-McCaughan, S., Shiroma, P. R., Purohit, P., Brundige, A., Murff, W., Ahn, K.-H., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01266-9 · Cited by 111
“Unfortunately, failed clinical trials due to high placebo response are not uncommon in this field (22).”
BackgroundLessons learned from placebo groups in antidepressant trials
Mora, M. C. S., Nestoriuc, Y., & Rief, W. (2011) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2010.0394 · Cited by 111
D, M. F. M., Thase, M. E., DeBattista, C., Doghramji, K., Arora, S., & Hughes, R. J. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701464858 · Cited by 110
“, diagnostic misclassification, rising or dwindling severity of symptoms over the natural course of illness, patient and clinician expectations) that may contribute to a placebo response, thereby confounding interpretation of efficacy assessments and decreasing the likelihood of detecting treatment differences in clin…”
BackgroundKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162].”
BackgroundBoucher, H. W., Ambrose, P. G., Chambers, H. F. “., Ebright, R. H., Jezek, A., Murray, B. E., Newland, J. G., Ostrowsky, B. E., Rex, J. H., & on behalf of the Infectious Diseases Society of America (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix211 · Cited by 105
“This approach is the intellectual inverse of the idea of sequential parallel comparison design, in which an initial screening step is used to remove placebo responders [45].”
Bugarski‐Kirola, D., Wang, A., Abi‐Saab, D., & Blaettler, T. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.007 · Cited by 103
“A strong placebo response is not an uncommon outcome in mental health clinical studies (Fava et al., 2003).”
Rethinking Models of Psychotropic Drug Action
Moncrieff, J., & Cohen, D. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000083999 · Cited by 96
Fava, G. A., Guidi, J., Rafanelli, C., & Rickels, K. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480038 · Cited by 93
The Clinical Global Impressions scale: errors in understanding and use
Busner, J., Targum, S. D., & Miller, D. S. (2008) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2008.08.005 · Cited by 92
“Given the high rate of failure of many CNS investigational drugs to separate from placebo [15-18], the reduction of error in the measure of efficacy is a critical clinical trials priority.”
BackgroundDocherty, J. P., Sack, D. A., Roffman, M., Finch, M., & Komorowski, J. R. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200509000-00004 · Cited by 90
Chen, Y., Yang, Y., Hung, H., & Wang, S. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.006 · Cited by 86
“In 2003, Fava proposed sequential parallel design (SPD) [2] to reduce both the placebo response and the required sample size for double-blind, placebo-controlled short-term psychiatric trials.”
BackgroundMethodInfluentialD, M. F. M., Thase, M. E., Trivedi, M. H., Ehrich, E. W., Martin, W. F., Memisoglu, A., Nangia, N., Stanford, A. D., Yu, M., & Pathak, S. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0284-1 · Cited by 86
Hammond, F. M., Sherer, M., Malec, J. F., ZAFONTE, R. D., Whitney, M. P., Bell, K. R., DIKMEN, S. S., Bogner, J. A., Mysiw, W. J., Pershad, R., et al. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3803 · Cited by 82
Blumberger, D. M., Vila-Rodriguez, F., Wang, W., Knyahnytska, Y., Butterfield, M., Noda, Y., Yariv, S., Isserles, M., Voineskos, D., Ainsworth, N. J., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.09.003 · Cited by 81
“This finding may be explained by the blinded nature of the trial [27], which is known to suppress response and remission rates, but may also be explained by a possible cancelling of the plasticity inducing effects by extending the iTBS session [28].”
The Intellectual Crisis of Psychiatric Research
Fava, G. A. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000092890 · Cited by 79
Contribution of spontaneous improvement to placebo response in depression: A meta-analytic review
Rutherford, B. R., Mori, S., Sneed, J. R., Pimontel, M. A., & Roose, S. P. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.02.008 · Cited by 79
Experimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 83
“To address this issue, several solutions are proposed, including the sequential parallel comparison design 12 and the use of external, blinded raters to assess clinical trial patients.”
MethodMasi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
An examination of the efficiency of the sequential parallel design in psychiatric clinical trials
Tamura, R., & Huang, X. (2007) · Clinical Trials · doi:10.1177/1740774507081217 · Cited by 75
“[2] suggested that responders after the first phase of the study be moved to open label continuation therapy.”
BackgroundMethodInfluentialLombardo, I., Sachs, G. S., Kolluri, S., Kremer, C. M. E., & Yang, R. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825ccde5 · Cited by 74
Kamijima, K., Higuchi, T., Ishigooka, J., Ohmori, T., Ozaki, N., Kanba, S., Kinoshita, T., & Koyama, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.07.035 · Cited by 80
“, 2002), and the list of potential contributing factors is wide and diverse (Fava et al., 2003).”
BackgroundBech, P., Tanghøj, P., Cialdella, P., Andersen, H. F., & Pedersen, A. G. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004365 · Cited by 74
“…by guest on 28 July 2018 is in agreement with our previous citalopram dose– response study (Bech et al., 2002) and which is in accordance with Fava et al. (2003) who concluded that the HAMD6 now seems to have outperformed the full HAMD as an outcome scale in trials of antidepressants.”
ResultAdvances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases
Cummings, J. L., Ritter, A. R., & Rothenberg, K. G. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1058-4 · Cited by 82
Modern Psychometrics in Clinimetrics: Impact on Clinical Trials of Antidepressants
Bech, P. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000076448 · Cited by 73
Dunlop, B. W., Thase, M. E., Wun, C., Fayyad, R. S., Guico‐Pabia, C. J., Musgnung, J. J., & Ninan, P. T. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.153 · Cited by 72
The Use of Placebo in Clinical Trials on Bipolar Disorder: A New Approach for an Old Debate
Vieta, E., & Carné, X. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000082021 · Cited by 70
“In addition, it should be remembered that response is measured with scales including some items which are more susceptible than others to the effects of suggestion or behavioural interventions. Thus, although mania, as a syndrome, may appear to have little susceptibility to improving with a placebo, some aspects of th…”
BackgroundPrognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R. R., Zarate, C. A., & Kasper, S. F. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18205 · Cited by 72
Amyotrophic lateral sclerosis disease progression model
Goméni, R., D, M. F. M., & The Pooled Resource Open-Access ALS Clinical Trials Consortium (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.838970 · Cited by 68
Li, S., Rong, P., Wang, Y., Jin, G., Hou, X., Li, S., Xiao, X., Zhou, W., Wu, Y., Liu, Y., et al. (2022) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2021.10.021 · Cited by 68
Sachs, G. S., Yeung, P. P., Rekeda, L., Khan, A., Adams, J., & D, M. F. M. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220504 · Cited by 67
“There are several common challenges (39) in MDD clinical trials that should be considered when interpreting FIGURE 2.”
BackgroundConfusing placebo effect with natural history in epilepsy: A big data approach
Goldenholz, D. M., Moss, R., Scott, J. M., Auh, S., & Theodore, W. H. (2015) · Annals of Neurology · doi:10.1002/ana.24470 · Cited by 67
“be very important for the development of new, and more effective, drug therapy in epilepsy and other disorders.(8,10) Placebo responses could involve several mechanisms.”
BackgroundMethodInfluentialMcPherson, S., Cairns, P., Carlyle, J., Shapiro, D. A., Richardson, P., & Taylor, D. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00498.x · Cited by 66
“(28) 17 CBT 6 weeks minimum `standard doses'; two episodes O 19 (16) Mean 15 € 4”
BackgroundGoméni, R., & Merlo‐Pich, E. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02815.x · Cited by 65
Response to placebo in clinical epilepsy trials—Old ideas and new insights
Goldenholz, D. M., & Goldenholz, S. R. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.02.002 · Cited by 69
Placebo effects in osteoarthritis: implications for treatment and drug development
Neogi, T., & Colloca, L. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01021-4 · Cited by 64
Optimality, sample size, and power calculations for the sequential parallel comparison design
Ivanova, A., Qaqish, B. F., & Schoenfeld, D. (2011) · Statistics in Medicine · doi:10.1002/sim.4292 · Cited by 64
“The test is similar in concept to that in [5], where a weight w is chosen to combine data from stages 1 and 2.”
BackgroundMethodResultInfluentialSelf-citationSignal Detection and Placebo Response in Schizophrenia: Parallels with Depression
Mallinckrodt, C. H., Zhang, L., Prucka, W. R., & Millen, B. A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4282 · Cited by 64
Dauphinais, D. R., Rosenthal, J. Z., Terman, M., DiFebo, H. M., Tuggle, C., & Rosenthal, N. E. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.01.015 · Cited by 63
Psychiatric sequelae of traumatic brain injury — future directions in research
Li, L. M., Carson, A. J., & Dams-O’Connor, K. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00853-8 · Cited by 65
Litten, R. Z., Castle, I. P., Falk, D. E., Ryan, M., Fertig, J. B., Chen, C. M., & Yi, H. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12197 · Cited by 63
“These include the use of placebo lead-ins, in which subjects are provided with the placebo in advance of study period; sequential parallel comparison design, which involves 2 phases of treatment, with nonresponders to the placebo during Phase 1 included in the efficacy analysis of Phase 2; and elimination of extreme p…”
BackgroundMethodD, M. F. M., Durgam, S., Earley, W. R., Lu, K., Hayes, R., Laszlovszky, I., & Németh, G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000235 · Cited by 67
“…or brexipiprazole augmentation trials with similar study designs (Berman et al., 2007, 2009; Marcus et al., 2008; Kamijima et al., 2013; Lenze et al., 2015; Thase et al., 2015a, 2015b), and high placebo response can reduce signal detection, which may lead to negative results (Fava et al., 2003).”
BackgroundUse of functional imaging across clinical phases in CNS drug development
Borsook, D., Becerra, L. R., & D, M. F. M. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.43 · Cited by 66
“tion of treatment outcome, waxing and waning of the natural course of illness, regression toward the mean phenomenon, study designs fostering high patient and clinician expectations, nonspecific therapeutic effects and high attrition rates.(9) Three of these elements are thought to represent the most critical factors…”
BackgroundPlacebo response in clinical trials with schizophrenia patients
Kinon, B. J., Potts, A. J., & Watson, S. B. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834381b0 · Cited by 62
McCann, D. J., Petry, N. M., Bresell, A., Isacsson, E., Wilson, E., & Alexander, R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000372 · Cited by 63
Sarris, J. J., Byrne, G. J., Stough, C. K. K., Bousman, C., Mischoulon, D., Murphy, J., MacDonald, P., Adams, L., Nazareth, S. M., Oliver, G., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.092 · Cited by 64
Placebos and the Placebo Effect in Drug Trials
Enck, P., & Klosterhalfen, S. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_269 · Cited by 60
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
The Ham D6 is more homogenous and as sensitive as the Ham D17
Lecrubier, Y., & Bech, P. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.01.1218 · Cited by 57
“As in other trials with antidepressants, the HAM-D17 was also in this study found to be a multidimensional scale, implying that the total score is not sufficient to verify whether a drug has antidepressive properties [2,6,8].”
ResultDoros, G. D., Pencina, M. J., Rybin, D. V., Meisner, A., & D, M. F. M. (2013) · Statistics in Medicine · doi:10.1002/sim.5728 · Cited by 55
“whereas Tamura and Huang used simulations to search for both w and the randomization unbalance in phase I (here chosen to be 2 W 1) to maximize the power [1, 14].”
BackgroundMethodInfluentialPorcelli, P., Carne, M. D., & Todarello, O. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000076454 · Cited by 55
Metadata
- Authors
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 72
- Issue
- 3
- Pages
- 115-127
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2073526412
- Cited by
- 452
- References
- 34
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 29 · 2019: 41 · 2018: 23 · 2017: 32 · 2016: 21 · 2015: 29 · 2014: 22 · 2013: 21 · 2012: 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, placebo effect, mental illness, clinical trial design, regression to the mean, attrition, sample size reduction, outcome measure sensitivity
- MeSH terms
- Mental Disorders, Clinical Trials as Topic, Double-Blind Method, Humans, Research Design, Reproducibility of Results, Placebo Effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.